We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-3.83%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$928M
AUM Growth
-$21.2M
Cap. Flow
+$44.5M
Cap. Flow %
4.8%
Top 10 Hldgs %
34.27%
Holding
87
New
4
Increased
25
Reduced
17
Closed
2

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$9.79M
2
CRL icon
Charles River Laboratories
CRL
+$9.03M
3
ISRG icon
Intuitive Surgical
ISRG
+$7.34M
4
PRCT icon
Procept Biorobotics
PRCT
+$7.3M
5
MDT icon
Medtronic
MDT
+$6.95M

Top Sells

Rank Stock Value
1
CI icon
Cigna
CI
+$9.98M
2
ZBH icon
Zimmer Biomet
ZBH
+$9.91M
3
ELV icon
Elevance Health
ELV
+$8.16M
4
UNH icon
UnitedHealth
UNH
+$6.89M
5
MOH icon
Molina Healthcare
MOH
+$6.54M

Sector Composition

Rank Sector Weight
1 Healthcare 99.51%
2 Industrials 0.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
1
Eli Lilly
LLY
$1.02T
$53.7M 5.79%
100,000
+19,000
+23% +$9.79M
BSX icon
2
Boston Scientific
BSX
$69.5B
$37M 3.98%
700,000
+120,000
+21% +$6.29M
BMRN icon
3
BioMarin Pharmaceuticals
BMRN
$11.6B
$33.6M 3.63%
380,000
– –
REGN icon
4
Regeneron Pharmaceuticals
REGN
$78.5B
$32.9M 3.55%
40,000
+5,000
+14% +$3.93M
MCK icon
5
McKesson
MCK
$100B
$30.9M 3.33%
71,000
– –
MDT icon
6
Medtronic
MDT
$109B
$29.4M 3.17%
375,000
+83,000
+28% +$6.95M
VRTX icon
7
Vertex Pharmaceuticals
VRTX
$121B
$26.6M 2.87%
76,500
+13,000
+20% +$4.55M
ABT icon
8
Abbott
ABT
$183B
$25.3M 2.73%
261,675
+12,675
+5% +$1.33M
BDX icon
9
Becton Dickinson
BDX
$45.6B
$24.6M 2.65%
95,000
– –
HUM icon
10
Humana
HUM
$43.7B
$23.8M 2.57%
49,000
+3,000
+7% +$1.41M
UNH icon
11
UnitedHealth
UNH
$376B
$23.2M 2.5%
46,000
-14,000
-23% -$6.89M
CI icon
12
Cigna
CI
$73.7B
$22.9M 2.47%
80,000
-34,985
-30% -$9.98M
ABBV icon
13
AbbVie
ABBV
$443B
$22.4M 2.41%
150,000
– –
THC icon
14
Tenet Healthcare
THC
$20.5B
$22.1M 2.38%
335,000
+45,000
+16% +$3.36M
COR icon
15
Cencora
COR
$60.6B
$21.4M 2.31%
119,000
– –
CVS icon
16
CVS Health
CVS
$133B
$20.9M 2.26%
300,000
+52,000
+21% +$3.68M
HCA icon
17
HCA Healthcare
HCA
$87.2B
$20.4M 2.2%
83,000
+18,500
+29% +$5.06M
ISRG icon
18
Intuitive Surgical
ISRG
$127B
$19.7M 2.13%
67,500
+23,500
+53% +$7.34M
MRK icon
19
Merck
MRK
$322B
$19.6M 2.11%
190,000
– –
COO icon
20
Cooper Companies
COO
$14.1B
$19.1M 2.06%
240,000
+28,800
+14% +$2.65M
JAZZ icon
21
Jazz Pharmaceuticals
JAZZ
$15.9B
$18.6M 2%
143,634
-1,366
-0.9% -$182K
GILD icon
22
Gilead Sciences
GILD
$162B
$17.5M 1.89%
234,000
– –
ELV icon
23
Elevance Health
ELV
$81.5B
$16.5M 1.78%
38,000
-18,000
-32% -$8.16M
PRCT icon
24
Procept Biorobotics
PRCT
$1.06B
$16.2M 1.74%
493,000
+214,000
+77% +$7.3M
SWAV
25
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$16.1M 1.74%
81,000
+25,000
+45% +$5.91M
1
2 3 4

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2023 Portfolio in Review

As of Q3 2023, Rhenman & Partners Asset Management held 87 positions worth $928M, down 2.2% from $949M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rhenman & Partners Asset Management deployed $44.5M of net new capital in Q3 2023, opening 4 new positions and adding to 25 existing holdings. Its largest new stake was Charles River Laboratories: 44,000 shares worth $8.62M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Cigna, an estimated $9.98M trimmed.

  • Rhenman & Partners Asset Management's largest Q3 2023 buy was Charles River Laboratories: 44,000 shares worth $8.62M.
  • Rhenman & Partners Asset Management added most to Eli Lilly in Q3 2023, an estimated $9.79M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2023 reduction was Cigna, cutting an estimated $9.98M.
  • Rhenman & Partners Asset Management fully exited Molina Healthcare in Q3 2023, selling an estimated $6.54M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 34% of its $928M portfolio in Q3 2023.
  • Rhenman & Partners Asset Management opened 4 new positions and closed 2 in Q3 2023.
  • Rhenman & Partners Asset Management's portfolio value fell 2.2% quarter-over-quarter to $928M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2023, filed 9 Nov 2023.